Cardiotoxicity of Epidermal Growth Factor Receptor 2-Targeted Drugs for Breast Cancer

ZiYan Yang†, Wei Wang‡, Xiaojia Wang§ and ZhiQuan Qin†*

†Department of Oncology Center, Oncology, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou, China, ‡Graduate School of Bengbu Medical College, Bengbu, China, §Department of Breast Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China

Breast cancer is the most common form of cancer in women and its incidence has been increasing over the years. Human epidermal growth factor receptor 2 (HER2 or ErbB2) overexpression is responsible for 20 to 25% of invasive breast cancers, and is associated with poor prognosis. HER2-targeted therapy has significantly improved overall survival rates in patients with HER2-positive breast cancer. However, despite the benefits of this therapy, its cardiotoxicity is a major concern, especially when HER2-targeted therapy is used in conjunction with anthracyclines. At present, the mechanism of this cardiotoxicity is not fully understood. It is thought that HER2-targeting drugs inhibit HER2/NRG 1 dimer formation, causing an increase in ROS in the mitochondria of cardiomyocytes and inhibiting the PI3K/Akt and Ras/MAPK pathways, resulting in cell apoptosis. Antioxidants, ACE inhibitors, angiotensin II receptor blockers, β-blockers, statins and other drugs may have a cardioprotective effect when used with ErbB2-targeting drugs. NT-proBNP can be used to monitor trastuzumab-induced cardiotoxicity during HER2-targeted treatment and may serve as a biological marker for clinical prediction of cardiotoxicity. Measuring NT-proBNP is non-invasive, inexpensive and reproducible, therefore is worthy of the attention of clinicians. The aim of this review is to discuss the potential mechanisms, clinical features, diagnostic strategies, and intervention strategies related to cardiotoxicity of ErbB2-targeting drugs.

Keywords: cardiotoxicity, ErbB2, targeting drugs, breast cancer, therapy

1 INTRODUCTION

Breast cancer is the most common cancer among women worldwide, and its incidence has been increasing yearly (Bray et al., 2018). Chemotherapy is one of the main treatments for breast cancer (Piccart-Gebhart and Sotiriou, 2007). Human epidermal growth factor receptor 2 (HER2), also known as erythroblast leukemia virus oncogene homolog 2 (ErbB2), is overexpressed in 20–25% of breast cancers. This transmembrane receptor promotes abnormal cell growth and proliferation in human breast cancer, leading to tumor cell invasion and poor prognosis (Slamon et al., 1987). HER2/ErbB2 are potential targets in chemotherapy of HER2-positive (HER2+) breast cancer. The 2021 ASCO Guidelines indicated that ErbB2-targeting drugs significantly improved survival rates and more patients were included in the range of drug (Korde et al., 2021). Unfortunately, target drugs is often discontinued once cardiotoxicity occurs during clinical (Perez and Rodeheffer, 2004). Cardiotoxicity is mainly caused by the reversible decrease of ejection fraction, but also severe heart failure and even fatal (Jerusalem et al., 2019).
HER2 belongs to a family of receptor tyrosine kinases with four members: HER1 (EGFR), HER2, HER3 and HER4. When activated, the HER proteins homodimerize or heterodimerize and subsequently activate intricate cellular signalling cascades, including the PI3K/AKT and RAS/MAPK (ERK) pathways, which regulate cell proliferation and survival, as well as the metastasis of tumour cells (Slamon et al., 1987). ErbB2-targeted drugs include monoclonal antibodies, antibody drug conjugates and tyrosine kinase inhibitors (Godeau et al., 2021). Monoclonal antibodies mainly include trastuzumab, pertuzumab and margetuximab. Trastuzumab, a humanized monoclonal antibody against ErbB2 domain IV was the first immunotherapeutic agent for HER2(+) breast cancer (Jerian and Keegan, 1999). Margetuximab is a novel anti-Herb2 antibody that has a higher affinity with the Fc receptor and stronger antibody-dependent cell-mediated antitumor cytotoxicity (ADCC) (Kaplon and Reichert, 2021). Pertuzumab is another humanized monoclonal antibody that binds to ErbB2 domain II and inhibits its dimerization (Capelan et al., 2013). Trastuzumab emtansine(T-DM1) and Trastuzumab deruxtecan (DS-2801,Enhertu) are anticytotoxic drug conjugates composed of trastuzumab with the microtubule toxin DM1 and topoisomerase I inhibitor, a potent mitotic inhibitor (Zhao et al., 2020; Andrikopoulou et al., 2021). T-DM1 is currently a second-line treatment for patients with metastatic HER2(+) breast cancer (Verma et al., 2012). The Tyrosine kinase inhibitors include lapatinib, Neratinib and Tucatinib (Chaar et al., 2018). Lapatinib is an oral tyrosine kinase inhibitor that reverses ErbB2 and endothelium growth factor receptor (EGFR orErB1) signaling (Moy et al., 2007). Neratinib is an irreversible small molecule inhibitor of HER1, HER2 and HER4 tyrosine kinases, approved for the extended adjuvant treatment of women with early-stage and metastatic HER2 + breast cancer (Oh and Bang, 2020). Tucatinib, a newly approved tyrosine kinase inhibitor, is characterized by its high selectivity for HER2/ErB2 (Corti and Criscitiello, 2021). In order to better understand the cardiotoxicity of ErbB2-targeted drugs, we have systematically reviewed recently published papers on the potential mechanisms, clinical manifestations, diagnostic strategies, intervention strategies, and the latest progress in ErbB2-targeted drug cardiotoxicity. We summarized the potential mechanism and intervention strategies with ErbB2/nauregulin 1 (NRG1) pathway causing cardiac dysfunction reported to date, to provide more evidence for clinical practice (Figure 1).

2 MECHANISM OF CARDIOTOXICITY

The ErbB receptor is a transmembrane receptor tyrosine kinase that regulates cell physiological responses including cell growth, division, differentiation, adhesion, function, and apoptosis (Linggi and Carpenter., 2006). ErbB signaling in the heart is critical for the normal development of the fetal heart (Gassmann et al., 1995). In mutant mice with a deletion of the ErbB2 gene, abnormal ventricular trabeculae resulted in fetal death (Lee et al., 1995; Meyer and Birchmeier, 1995). In addition, ErbB2 plays an important role in adult cardiomyocytes growth (Zhao et al., 1998). ErbB2 mutant mice showed decreased ErbB2 expression and impaired ventricular dilation and contraction, and histology of the myocardium revealed ultrastructural changes (Ozcelik et al., 2002). Trastuzumab and pertuzumab reduced the dimerization of ErbB2/4 in rat and human cardiomyocytes (Fedele et al., 2012a). The NRG-1/ErbB2/Erbb4 complex controls cardiomyocyte survival and myofibrillary disorders in cardiomyocytes (Kuramochi et al., 2006). NRG-1 activation directly promotes cardiomyocyte survival through the ErbB2/ERBB4 heterodimer (De Keulenaer et al., 2010). NRG1 activates PI3-kinase/Akt and MAPK/Erk1/2 pathways through ErbB2 phosphorylation.
Silencing or down-regulation of ErbB2 expression attenuated NRG-1-induced intracellular Akt and ERK1/2 phosphorylation (Hsu et al., 2018). NRG1 is a ligand of the epidermal growth factor family, which can bind to ErbB3 or ErbB4 monomers and induce the formation of homodimers (ErbB4/4) and heterodimers (ErbB2/3 or ErbB2/4) (Lemmens et al., 2007). The NRG1 stimulates glucose uptake and protein synthesis in cardiomyocytes. (Cote et al., 2005). ErbB2 inhibition decreased expression of endothelial nitric oxide synthase (eNOS) and increased inducible nitric oxide synthase (iNOS), leading to produce more reactive oxygen species (ROS) (Timolati et al., 2006). NRG1 reduces contraction without impairing diastole by upregulating NOS and reducing the effect of β-adrenergic stimulation (Lemmens et al., 2004). STAT-3 is a transcription factor that is activated by tyrosine phosphorylation in response to certain ligand, such as interferon and epidermal growth factor (Tkach et al., 2013). It plays a key role in cell growth and differentiation, leading to ultrastructural changes in cardiomyocytes (Kabel and Elkhoely, 2017). ErbB2 inhibition can lead to increased Bcl-xS/Bcl-xL ratio, activation of mitochondrial caspase-9 and caspase-3, and causing apoptosis (Rohrbach et al., 2005). ErbB2 inhibition has also been reported to alter Bcl-x splicing, induce endogenous apoptotic signaling (Grazette et al., 2004; De Lorenzo et al., 2018). Besides, Matrix metalloproteinase-2 (MMP2) mRNA is elevated in trastuzumab cardiotoxicity, accompanied by an increase in ROS (Riccio et al., 2018). Lapatinib can affect cardiac function and fibrosis in mice (Fedele et al., 2012b). Lapatinib can directly inhibit ErbB2 phosphorylation (Sawyer et al., 2002). Although lapatinib did not affect NOS expression and basal mitochondrial respiration, it impaired the standby oxygen consumption rate (Hsu et al., 2018). Cardiotoxicity caused by the inhibition of ErbB2 may be due to the adaptation of the heart to stress reactions. There is evidence that trastuzumab, pertuzumab, and lapatinib reduce cell viability in a concentration-dependent manner (Fedele et al., 2012a). Furthermore, ErbB2 inhibition increased ROS production and impaired mitochondrial function in a concentration-dependent manner (Pentassuglia et al., 2007) (Figure 2).

### 3 CLINICAL FEATURES OF CARDIOTOXICITY

#### 3.1 Monoclonal Antibody

The main reason for discontinuation of ErbB2-targeted therapy is cardiotoxicity (Martin et al., 2009). Trastuzumab was the first ErbB2-targeting drug to be used in HER+ breast cancer, therefore, trastuzumab-associated cardiotoxicity is the most well-studied cardiotoxicity of the cardiotoxities associated with Erb2-targeting drugs (Herrmann, 2020). Trastuzumab-associated cardiotoxicity is usually characterized by an asymptomatic decrease in left ventricular ejection fraction (LVEF), which can be reversed after drug discontinuation (Perez and Rodeheffer, 2004). However, a prospective study showed that 48.53% of patients with available cardiac
TABLE 1 | Summary of studies for development of clinical HER-2 target drugs.

| Author/Date          | Trial type        | Population studies                        | Number | Methods                                                                 | Significant                                                                 | References                                                                 |
|----------------------|-------------------|-------------------------------------------|--------|-------------------------------------------------------------------------|------------------------------------------------------------------------------|----------------------------------------------------------------------------|
| Jacquino et al. (2018) | Prospective study | Patients who received 12 months of trastuzumab | 1631   | LVEF performed every 3 months; every 6 months (patients received trastuzumab and after completion of treatment over the first 2 years) | Non-recovered LVD was associated with MACEs. Decreased LVEF, enlarged LV size, pulmonary hypertension, and anaemia were independent predictors of LV-functional non-recovery | Jacquino et al. (2018) |
| Yoon et al. (2019)   | Retrospective study | Patients with trastuzumab-induced left ventricular dysfunction (LVD) | 243    | Major adverse clinical events (MACEs) were compared in non-recovered LVD and recovered LVD. | Impaired baseline cardiac function experience no higher risk of LVEF decline, but more frequently develop symptomatic heart failure | Yoon et al. (2019) |
| Nowshen et al. (2018) | Retrospective study | Patients with reduced left ventricular ejection fraction during using trastuzumab | 428    | A retrospective study of women treated with trastuzumab for human epidermal growth factor receptor 2 breast cancer at Mayo Clinic Rochester between January 1, 2000 and August 31, 2015 with pre- and on-therapy echocardiograms available for review | Lower LVEF before trastuzumab independently predicted subsequent development of TRC | Nowshen et al. (2018) |
| Hussain et al. (2019) | Retrospective study | Patients with reduced left ventricular ejection fraction during using trastuzumab | 160    | Retrospectively studied 160 patients with breast cancer receiving trastuzumab in the adjuvant (n = 129) as well as metastatic (n = 31) settings in our institution from 2006 to 2015. During the median follow-up of 3.5 years | The obese group was more prone to cardiotoxicity than the normal-weight group. Obesity and administration of trastuzumab were independently associated with cardiotoxicity | Hussain et al. (2019) |
| Kaboré et al. (2019) | Prospective study  | Patients with stage I–III BC treated with anthracycline and/or trastuzumab | 929    | Analyzed associations between BMI and cardiotoxicity using multivariate logistic regression | Deformation mechanics of both the left and right ventricle follow similar temporal pattern and degree of impairment, confirming the global and uniform effect of trastuzumab on myocardial function | Kaboré et al. (2019) |
| Keramida et al. (2019) | Prospective study | Patients with consecutive receiving trastuzumab for 12 months | 101    | Comprehensive two-dimensional echocardiography with speckle tracking imaging of LV and RV global longitudinal strain (GLS) and RV free wall longitudinal strain (FWLS) analyses were performed at baseline and every 3 months up to treatment completion | The obese group was more prone to cardiotoxicity than the normal-weight group. Obesity and administration of trastuzumab were independently associated with cardiotoxicity | Keramida et al. (2019) |

TABLE 2 | Summary of studies for toxicities of HER-2 target drugs.

| ERBB2-Targeted drugs | Toxicities                                                                 | References                                                                 |
|-----------------------|---------------------------------------------------------------------------|----------------------------------------------------------------------------|
| Monoclonal antibody   | Trastuzumab: LVEF decreased, HF happened, Arrhythmia                       | Romond et al. (2012), Bayar et al. (2015), Serrano et al. (2015), Jacquino et al. (2018), Nowshen et al. (2018), Hussain et al. (2019), Keramida et al. (2019), Yoon et al. (2019), Upshaw et al. (2020) |
|                       | Pertuzumab: Neutropenia and diarrhea                                       | van Ramshorst et al. (2016), Tan et al. (2021) |
|                       | Trastuzumab: LVEF decreased, HF happened, Arrhythmia                       | Romond et al. (2012), Bayar et al. (2015), Serrano et al. (2015), Jacquino et al. (2018), Nowshen et al. (2018), Hussain et al. (2019), Keramida et al. (2019), Yoon et al. (2019), Upshaw et al. (2020) |
| Antibody-drug conjugates | Trastuzumab: LVEF decreased                                               | Markham (2021) |
|                       | Pertuzumab: Neutropenia and diarrhea                                       | Krop et al. (2014), Pondé et al. (1990), Perez et al. (2017), von Minckwitz et al. (2019) |
|                       | Margaritumab: Dianhooa, nausea, anaemia and pyrexia                       | Modi et al. (2020) |
|                       | T-DM1: Transient LVEF decreased                                            | Markham (2021) |
|                       | DS-8201: Anaemia, neutropenia, thrombocytopenia, leukopenia, and interstitial lung disease or pneumonia | Bilancia et al. (2007), de Azambuja et al. (2014), Eiger et al. (2020) |
| Tyrosine kinase inhibitors | Lapatinib: Mild diarrohea and rash                                         | Avada et al. (2016), Chau et al. (2016), Martin et al. (2017) |
|                       | Neratinib: Dianhooa                                                       | Lee (2020), Shah et al. (2021) |
|                       | Tucatinib: Dianhooa and hepatotoxicity                                     | Avada et al. (2016), Chau et al. (2016), Martin et al. (2017) |

LVEF, left ventricular ejection fraction; HF, heart failure; T-DM1, Trastuzumab emtansine; DS-8201, Trastuzumab deruxtecan.
TABLE 3 | Summary of intervening measure. Current interventions are mainly antioxidants, ACER/AEB/BB and new material combination drugs. Antioxidants are made up of Probiucol, Ranoilazine, flaxseed (FLX), alpha-linolenic acid (ALA), secoisolariciresinol diglucoside (SDG), the antioxidant coenzyme Q(10) and nanoemulsion (NES). The possible mechanism is mainly antioxidant effect. The drugs mainly affected reactive oxygen species (ROS) accumulation to inhibit of cell death.

| Types       | Drugs       | Test subjects | Function                    | References           |
|-------------|-------------|---------------|-----------------------------|----------------------|
| Antioxidant | Probiucol   | Rats          | ROS↓/Myocardial remodeling↓ | PMID:21353471        |
|             | Ranoilazine | Mice          | MMMP2/Caspase3↓             | PMID:29467663        |
|             | FLX/ALA/SDG | Mice          | Antioxidant                 | PMID:32510147        |
|             | Q(10)+NES  | Humans        | LTBI↓/NF-κB/LI-6↓           | PMID:32764923        |
| ACER/ARB/BB | ACER/ARB    | —             | RASS↓/Myocardial remodeling↓| PMID:32777728        |
|             | BB          | —             | Sympathetic nervous↓       | PMID:32777728        |
|             | BB          | Mice          | Sirtuin-3↓/ROS↓             | PMID:35529501        |
|             | Statin      | —             | GS-SG↓/ROS↓                 | PMID:28622591        |
|             | Lipidosome  | Cells/Humans  | Cardiotoxicity↓             | PMID:26759238        |

ultrasound measurements (379 out of 781 patients) did not fully recover baseline LVEF (Jacquinot et al., 2018). Nonetheless, more than 30% of the people in the study were 60 years old. Therefore, the failure to exclude elderly patients with heart diseases from the study may have caused bias. Unfortunately, the study did not conduct a follow up, so long-term LVEF recovery results were not available. However, Yoon et al. found that non-recovery of trastuzumab-induced left ventricular dysfunction (LVD) had an impact on the clinical outcome of breast cancer. The survival rates of the group without left ventricular hypertrophy were significantly lower than those of the group with left ventricular hypertrophy. Increased left ventricular volume, pulmonary hypertension, and anemia were found to be contributing factors (Yoon et al., 2019). A recent study indicated that patients with reduced baseline cardiac function undergoing trastuzumab therapy for breast cancer developed symptomatic heart failure more frequently than patients with normal cardiac function, but did not experience a higher risk of LVEF decline (Nowsheen et al., 2018). These results contradict a previous study by Romond et al. (2012), that detected LVEF decline during trastuzumab treatment. However, the latter study tracked patients for up to 5 years and this may be the main reason for the opposing results. The development of diastolic dysfunction after treatment with anthracyclines, or anthracycline plus trastuzumab, is common (Serrano et al., 2015). However, the development of diastolic dysfunction was not observed with trastuzumab alone (Upshaw et al., 2020). Trastuzumab may cause right heart failure and right ventricular dysfunction and its effect on myocardial function was global and uniform (Bayar et al., 2015; Keramida et al., 2019). Hussain et al. found that patients with asymptomatic LVEF decline to <50% continued to use trastuzumab, who are expected to benefit from additional anti-HER2 therapy (Hussain et al., 2019).

Pertuzumab, in combination with other drugs, mostly causes neutropenia and diarrhea. Significant cardiac toxicity is rare with both regimens, and overall toxicity is manageable (van Ramshorst et al., 2016). Tan et al. (2021) obtained the same result and the occurrence of cardiotoxic events was less than 1%. Lynce et al. (2019) observed no statistical difference in the incidence of adverse cardiac events between pertuzumab combined with trastuzumab and trastuzumab alone. This was consistent with the results of two previous prospective studies (von Minckwitz et al., 2017). Pertuzumab may only inhibit ErbB2/3 dimerization but does not block the ErbB2/4 signalling pathway in cardiomyocytes (Franklin et al., 2004).

The safety of margetuximab combined with chemotherapy was considered to be acceptable, and margetuximab improved primary progression-free survival (PFS) compared with trastuzumab, with a 24% relative risk reduction (Rugo et al., 2021). In December 2020, margetuximab was approved by the United States Food and Drug Administration (FDA) for use in combination with chemotherapy for metastatic HER2+ breast cancer (Markham, 2021). Treatment was well-tolerated, with toxicities mostly consisting of constitutional symptoms such as diarrhea, nausea, anemia, and pyrexia. A phase I study found no LVEF reduction to <50% or symptomatic heart failure with the use of margetuximab (Bang et al., 2017). Primary analysis of results of the phase III Sophia trial, reported that the incidence of LVEF of any grade was lower in the margetuximab group, than in the trastuzumab group (Rugo et al., 2019).

3.2 Antibody–Drug Conjugates

The incidence of cardiac events (CEs) was low in patients treated with trastuzumab emtansine (T-DM1) (Krop et al., 2014). The latest meta-analysis included individual patient-level data of 1,961 patients exposed to T-DM1 from seven trials. Multivariate analysis showed age ≥65 years (OR 3.0; 95% CI, 1.77–5.14; p < 0.001) and baseline LVEF <55% (OR 2.62; 95% CI, 1.29–5.32; p = 0.008) as risk factors. The majority (79%) of patients had CE resolution after discontinuation of treatment (Pondé et al., 1990). The Phase III Marianne trial compared T-DM1 to T-DM1 + pertuzumab and trastuzumab + taxane, and both T-DM1-containing regimens (0.8 and 2.5%, respectively) had a lower incidence of LVEF reduction than the trastuzumab regimen (4.5%) (Perez et al., 2017). In the Katherine trial, cardiac adverse events were very rare overall (0.3%), but the incidence of T-DM1 (1 in 740) was still lower than that of trastuzumab (4 per 720) (von Minckwitz et al., 2019).

Trastuzumab deruxtecan (DS-8201) was approved by the FDA for the treatment of unresectable or metastatic HER2-positive breast cancer in December 2019 (Narayan et al., 2021). Trastuzumab deruxtecan rarely causes cardiotoxic events, and the most common adverse effects are hematological, including...
anemia, neutropenia, thrombocytopenia, and leukopenia. Other adverse effects include interstitial lung disease and pneumonia (Modi et al., 2020).

### 3.3 Tyrosine Kinase Inhibitors

Lapatinib is well tolerated and has a low incidence of cardiotoxicity, with mild diarrhea and rash being the most common toxic effects (Bilancia et al., 2007; de Azambuja et al., 2014). Eiger et al. (2020) discovered that compare trastuzumab (T) with galapatinib (L) dual HER2-blocking treatment to trastuzumab, CE was observed in 363 (8.6%) and 166 (7.9%) patients in the T + L arm versus 197 (9.3%) in the T arm (OR = 0.85; [95% CI, 0.68–1.05]).

Neratinib had a bigger problem—diarrhoea in clinical (Chan et al., 2016). In the Nefert-T study, the incidence of grade 3 or higher cardiotoxicity was 1.3% in the neratinib/paclitaxel group and 3.0% in the trastuzumab/paclitaxel group (Awada et al., 2016). In the Extenet trial, and no long-term cardiovascular toxicity was observed. Although cardiotoxicity is negligible, other obvious adverse events, such as diarrhea, require clinician attention (Martin et al., 2017).

Diarrhea and hepatotoxicity were reported as the major adverse events of tucatinib (Lee, 2020). On April 2020, the FDA approved tucatinib in combination with trastuzumab and capecitabine for the treatment of patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases (Shah et al., 2021). In the HER2CLIMB phase III trial, cardiotoxicity was less than 1% in both groups of participants (Murthy et al., 2020).

The latest individual patient data level pooled analysis of HERA, NSBAP B-31, and NCCTG 9831 (Alliance Trials) revealed baseline risk factors that were significantly associated with the development of CE. These factors were baseline LVEF <60%, hypertension, body mass index > 25, age ≥ 60 years, and non-Caucasian ethnicity (de Azambuja et al., 2020). In addition, Jones et al. (2018) found that cardiac function in the first 3 months after trastuzumab treatment had an impact on the long-term assessment of heart failure (6–24 months after treatment), and patients with no significant decrease in EF at 3 months tended to have better long-term assessment of heart failure. The French national multicentre prospective CANTO (CANCer TOxicities) study showed that obesity appears to be associated with an important increase in risk-related cardiotoxicity, which is consistent with the results of meta-analysis (Kaboré et al., 2019) (Tables 1.2).

### 4 DIAGNOSTIC STRATEGIES

#### 4.1 Imaging

Cardiac ultrasonography is the main method to detect heart failure caused by cardiotoxicity (Fallah-Rad et al., 2011). Impairment of the left ventricular diastolic function before treatment is an independent predictor of trastuzumab cardiotoxicity, and assessment of diastolic function before administration predicts cardiotoxicity risk (Cochet et al., 2011). Moreover, diastolic dysfunction was more sensitive than left ventricular ejection fraction on radiographic examination (Cao et al., 2015). Global longitudinal strain (GLS) analysis can detect cardiac changes earlier and more comprehensively (Lorenzini et al., 2017). A retrospective study showed that anthracycline trastuzumab treatment resulted in early worsening of left ventricle GLS, peripheral strain, and systolic strain rate and the right ventricle GLS and strain rate are also affected. However, early changes in GLS are a good predictor of cardiotoxicity (Arciniegas Calle et al., 2018). GLS based on the 3-apex viewpoint is the preferred technique for detecting cardiac toxicity (Ben Kridis et al., 2020). The latest meta-analysis, including 21 studies comprising of 1782 patients treated with anthracyclines with or without trastuzumab, found the high-risk cut-off values ranged from −21.0 to −13.8%, with worse GLS associated with a higher cancer therapy-related cardiac dysfunction (CTRCD) risk (odds ratio, 12.27; 95% CI, 7.73–19.47; area under the HSROC, 0.86; 95% CI, 0.83–0.89) (Oikonomou et al., 2019). Patients with persistent worsening in diastolic function while taking breast cancer chemotherapeutic agents have a small risk of subsequent systolic dysfunction (Upshaw et al., 2020). There are two new prospective studies comparing variability of echocardiography and cardiovascular magnetic resonance (CMR) in detecting cardiac dysfunction associated with cancer chemotherapy, but the results of these studies are inconclusive (Lambert et al., 2020; Houbois et al., 2021). Therefore, 2D-GLS appears to be the most suitable for clinical applications in individual patients.

#### 4.2 Biological Markers

With increasing research, the detection of cardiotoxicity is not limited to imaging, and the use of biological markers is becoming more common in clinical practice (Upshaw, 2020). Placental growth factor (PLGF), growth differentiation factor 15 (GDF-15), high-sensitivity C-reactive protein (hs-CRP), myeloperoxidase (MPO), and troponin I (TnI) can predict decreased LVEF and are promising biomarkers for detecting cardiac function (Onitilo et al., 2012; Bonnie et al., 2014; Putt et al., 2015). A sub-study of the NEOALTTO trial suggested troponin T (TnT) and the amino-terminal fragment of brain natriuretic peptide (NT-proBNP) do not provide an early predictor of cardiac toxicity (Ponde et al., 2018). Besides, a meta-analysis found that an increase in the average BNP/NT-proBNP level of patients after treatment cannot predict left ventricle dysfunction (Michel et al., 2020). But, the latest prospective study, the NEOALTTO trial, fifty newly diagnosed human epidermal growth factor receptor 2-positive BC women received or did not receive anthracycline followed by taxus and trastuzumab for 15 months of follow-up, found NT-pro-BNP measured at the completion of anthracyclines are useful in the prediction of subsequent TIC (Ben Kridis et al., 2020). The NEOALTTO trial had only 11 study patients and receiving trastuzumab and lapatinib two targeted therapies may be the factors. Moreover, the meta-analysis research object is all tumor patients, not just breast cancer and BNP is more susceptible compared to NT-proBNP. The circulating level of NT-proBNP is increased in the unselected cancer patient population, which is related to the increase of myocardial performance index (MPI).
value, and is closely related to all-cause mortality (Yıldırım et al., 2013; Pavo et al., 2015). GeparOcto-GBG 84 Trial also found a small but significant increase in early NT-proBNP levels in patients with cardiotoxic reactions. NT-proBNP and haemoglobin were significantly associated with cardiotoxicity in patients receiving dose-intensive chemotherapy for early-stage breast cancer, whereas hypersensitive cardiac troponin T was not (Rüger et al., 2020). This may be because direct necrosis of the heart tissue results in more cardiomyocyte dysfunction, as well as the short half-life of TnI and systematic errors caused by experimental design and detection technology. Andersson et al. (2021) found the sensitivity and specificity of NT-proBNP in the detection of trastuzumab induced cardiotoxicity (TIC) were 100 and 95% and changes in NT-proBNP may be used to monitor TIC in patients receiving trastuzumab treatment. They also provide a prognostic value (Pudil et al., 2020). Therefore, NT-proBNP level is an indicator worthy of clinical attention.

5 PREVENTIVE MEASURES

5.1 Antioxidants

ErbB2-targeting drugs are widely used and an increasing measures for prevention and treatment of cardiotoxicity are being investigated (Dias et al., 2016). Prophylaxis of the antioxidant Probucol (Prob) resulted in a 50% reduction in trastuzumab-treated mice with no significant reduction in left ventricular size or contraction parameters (Walker et al., 2011). In addition, renorizine can also inactivate the cardiotoxicity of trastuzumab by inhibiting the accumulation of ROS through redox-mediated mechanisms. Renolazine also reduced the side effects of pertuzumab and TDM1 (De Lorenzo et al., 2018). Surprisingly, dietary supplementation of flaxseed (FLX), alpha-linolenic acid (ALA), and secoisolariciresinol diglucoside (SDG) also appeared to have cardioprotective effects (Asselin et al., 2020). Similarly, the incorporation of the antioxidant coenzyme Q (10) into nanoemulsion (NES) reduced the expression of leukotriene B4 and p65/nuclear factor-kappa B (NF-kB) and the production of interleukin-1β and interleukin-6 to protect the heart (Quagliariello et al., 2020).

5.2 ACEIs/ARBs and BB

The combination of ACEIs/ARBs and BB (ACE inhibitors, angiotensin II receptor blockers and beta-blockers) with trastuzumab adjuvant therapy is beneficial for LVEF recovery (Oliva et al., 2012). ACEI/ARB can change the neurohumoral renin-angiotensin-aldosterone system (RAAS) pathway and prevent heart remodelling. Beta-blockers reduce sympathetic dysfunction (Elghazawy et al., 2020). However, metoprolol had no effect on the overall decline in LVEF (Gulati et al., 2016). It cannot prevent the decrease in LVEF, nor can it prevent severe heart atrophy, heart necrosis, or heart remodelling caused by chemotherapy (Nicol et al., 2021). Beta-1 adrenergic blockade may inhibit sirtuin-3 activation and promote oxidative stress, reducing the protective effect of the sirtuin-3 pathway on mitochondrial function and fibrosis (Guglin et al., 2019). Lisinopril or carvedilol was used to minimize the interruption of trastuzumab. Further prospective studies are required to verify whether this prophylaxis prevents trastuzumab-related cardiac toxicity.

5.3 Statins

Statins reduce the risk of heart failure due to anthracycline (Seicean et al., 2012). A recent retrospective study found that statins also reduced the decline in LVEF caused by trastuzumab. A total of 129 patients with HER2-positive breast cancer were treated with desuximab. Forty-three patients were treated with statins during the cancer treatment. The median trastuzumab exposure time was 11.8 months (range, 11–12 months). Compared with the control group, the adjusted final LVEF was lower during a median cardiac follow-up of 11 months (IQR 9–18 months) (61.2 versus 64.6%, p = 0.034) (Calvillo-Argüelles et al., 2019). Statins reduce the risk of heart failure after chemotherapy for early breast cancer (including anthracyclines), but the risk associated with the use of statins after trastuzumab treatment remains unclear. Currently, the mechanism underlying the effect of statins on ErbB2-targeted cardiotoxicity remains unclear (Abdel-Qadir et al., 2021). However, one trial found that rosuvastatin inactivates the deterioration of left ventricular function and the production of reactive oxygen species (ROS) and glutathione. Therefore, the pleiotropic effects of HMG-CoA reductase inhibitors may be related (Kabel and Elkhoely, 2017).

5.4 Others

In addition, various other methods have been reported to reduce cardiotoxicity. Cardiac monitoring in patients receiving ErbB2-targeted therapy should be a priority (Henry et al., 2018). Monitoring of LVEF for 3 months was considered mandatory (Visser et al., 2016). Strict adherence to guidelines is necessary to avoid serious cardiovascular events. SAFE-HEArT, a long-term follow-up study, found that continued multidisciplinary care of patients with cancer and heart disease was essential to improve patient outcomes (Khoury et al., 2021). In addition, there was no significant difference in the incidence of adverse events between subcutaneous and intravenous administration, and it was safe and tolerable in HER2-positive early/locally advanced breast cancer (EBC/LABC) (Zambetti et al., 1990; De Sanctis et al., 2021). Surprisingly, moderate-intensity exercise training in patients prevented LVEF and loss of strength (Hojan et al., 2017) (Table 3).

6 DISCUSSION

ErbB2-targeted drugs cause cardiac dysfunction that is exacerbated when combined with anthracycline chemotherapy for HER2-positive breast cancer. Although cardiotoxicity causes ultrastructural damage to the myocardium, the death of cardiomyocytes was found pathologically. Currently, the mechanism of cardiotoxicity remains unclear. However, the targeted drugs lead to an increase in mitochondrial ROS, activation of endogenous apoptotic procedures, and inhibition of NGR1/HER-2.
affecting downstream PI3K/Akt and Ras/MAPK pathways which provide possible explanations for the clinical protective effect of antioxidant drugs. MMP2 is a newly discovered target, which is mainly related to apoptosis. This is similar to the previous discovery of the BCL pathway. Myocardial toxicity and cell apoptosis deserve further study. These molecular structures may be potential therapeutic targets. Current interventions mainly include antioxidants, ACER/ARB/BB, and new material combination drugs. This protective effect may be achieved by reducing the accumulation of mitochondrial ROS. They have been shown to reduce the risk of cardiotoxicity in clinical and animal studies as antioxidants, but there is no further evidence of their roles in the ErbB2-induced pathway. More experiments are needed to verify whether these drugs act on the ErbB2-induced pathway. The main clinical symptom is decreased LVEF, but right ventricular dysfunction has also been reported, and the type of damage caused by cardiotoxicity to cardiomyocytes still further investigation. Risk factors significantly associated with the development of cardiac events were baseline LVEF <60%, hypertension, body mass index >25, age ≥60, and non-Caucasian ethnicity. They are the easiest and most significant indicators for assessing cardiotoxicity before the use of targeted drugs. Whether used alone or in combination, trastuzumab has more severe cardiotoxicity in ErbB2-targeted drugs than other drugs. While pertuzumab, margetuximab, antibody-drug conjugates, and tyrosine kinase inhibitors show less cardiotoxicity, other side effects like diarrhoea, rashes, and blood problems can also be a barrier to taking the medicine. Of course, high cost is also one of the factors that keeps patients away. The cardiotoxicity of trastuzumab combined with pertuzumab is low, but the cardiotoxicity of trastuzumab combined with lapatinib is higher. It is possible that lapatinib directly inhibits ErbB2 phosphorylation, while trastuzumab and pertuzumab have similar ErbB2 epitope-binding sites. Routine detection of LVEF and early presentation of Gls with ErbB2-targeted therapy can predict the development of cardiotoxicity. NT-proBNP has always been a hot marker in the predictive diagnosis of myocardial toxicity. Although there are still contradictory results in all tumor myocardial toxicity studies, it has good specificity and sensitivity in the treatment of breast cancer resulting in myocardial toxicity. NT-proBNP may be used to monitor TIC during treatment and has a predictive effect on TIC prognosis. It is non-invasive, inexpensive, reproducible, and worthy of the attention of clinicians. NT-proBNP may serve as a biological marker for clinical prediction of the occurrence of cardiotoxicity.

**AUTHOR CONTRIBUTIONS**

ZY supervised the writing of the manuscript; WW and ZY prepared the manuscript and wrote the draft together; WW prepared the figures and tables. WW and ZY contributed equally to this work. All authors have read and agreed to the published version of the manuscript.

**ACKNOWLEDGMENTS**

The authors thank all of the individuals who participated in the investigations.

**REFERENCES**

Abdel-Qadir, H., Bobrowski, D., Zhou, L., Austin, P. C., Calvillo-Argüelles, O., Amir, E., et al. (2021). Statin Exposure and Risk of Heart Failure after Anthracycline-or Trastuzumab-Based Chemotherapy for Early Breast Cancer: A Propensity Score-Matched Cohort Study. J. Am. Heart Assoc 10 (2), e018393. doi:10.1161/JAHA.119.018393

Andersson, A. E., Linderholm, B., and Gilgio, D. (2021). Delta NT-proBNP Predicts Cardiotoxicity in HER2-Positive Breast Cancer Patients Treated with Trastuzumab. Acta Oncologica 60, 475-481. doi:10.1080/0284186X.2020.1842904

Andrikkopoulou, A., Zografos, E., Liotios, M., Koutsoukos, K., Dimopoulos, M. A., and Zagouri, F. (2021). Trastuzumab Deruxtecan (DS-8201a): The Latest Research and Advances in Breast Cancer. Clin. Breast Cancer 21 (3), e212-e219. doi:10.1016/j.cbc.2020.08.006

Arciniegas Calle, M. C., Sandhu, N. P., Xia, H., Cha, S. S., Pellikka, P. A., Ye, Z., et al. (2018). Two-dimensional Speckle Tracking Echocardiography Predicts Early Subclinical Cardiotoxicity Associated with Anthracycline- or Trastuzumab Chemotherapy in Patients with Breast Cancer. BMC cancer 18, 1037. doi:10.1186/s12885-018-4935-z

Asselin, C. Y., Lam, A., Cheung, D. Y. C., Eckhoudt, C. R., Zhu, A., Mittal, I., et al. (2020). The Cardioprotective Role of Flaxseed in the Prevention of Doxorubicin- and Trastuzumab-Mediated Cardiotoxicity in C57BL/6 Mice. J. Nutr. 150 (9), 2353–2363. doi:10.1093/jn/nxaa144

Awada, A., Colomer, R., Inoue, K., Bondarenko, I., Badwe, R. A., Demetriou, G., et al. (2016). Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The

NEJERT-T Randomized Clinical Trial. JAMA Oncol. 2, 1557–1564. doi:10.1001/jamaoncol.2016.0237

Bang, Y. J., Giaccone, G., Im, S. A., Oh, D. Y., Bauer, T. M., Nordstrom, J. L., et al. (2017). First-in-human Phase 1 Study of Margetuximab (MGH22), an Fc-Modified Chimeric Monoclonal Antibody, in Patients with HER2-Positive Advanced Solid Tumors. Ann. Oncol. 28 (4), 855–861. doi:10.1093/annonc/mdx002

Bayar, N., Küçükseymen, S., Göktaş, S., and Arslan, Ş. (2015). Right Ventricle Failure Associated With Trastuzumab. Ther. Adv. Drug Saf. 6 (3), 98–102. doi:10.17177/2042098615582162

Ben Kridis, W., Charfeidinne, S., Toumi, N., Daoud, J., Kammoun, S., and Khanfir, A. (2020). A Prospective Study about Trastuzumab-Induced Cardiotoxicity in HER2-Positive Breast Cancer. Am. J. Clin. Oncol. 43 (7), 510–516. doi:10.1097/COC.0000000000000699

Bilancio, D., Rosati, G., Dinota, A., Germano, D., Romano, R., and Manzione, L. (2007). Lapatinib in Breast Cancer. Ann. Oncol. 18 Suppl 6 (Suppl 6), vi26–30. doi:10.1093/annonc/mdm220

Bonnie, K., Putt, M., Sawaya, H., French, B., Januzzi, J. L., Sebag, I. A., et al. (2014). Early Increases in Multiple Biomarkers Predict Subsequent Cardiotoxicity in Patients with Breast Cancer Treated with Doxorubicin, Taxanes, and Trastuzumab. J. Am. Coll. Cardiol. 63, 809–816. doi:10.1016/j.jacc.2013.10.061

Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., and Jemal, A. (2018). Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 68 (6), 394–424. doi:10.3322/caac.21492

Calvillo-Argüelles, O., Michalowska, M., Billia, F., Suntheralingam, S., Amir, E., and Thavendiranathan, P. (2019). Cardioprotective Effect of Statins in Patients
with HER2-Positive Breast Cancer Receiving Trastuzumab Therapy. *Can. J. Cardiol.* 35 (2), 153–159. doi:10.1016/j.cjca.2018.11.028

Cao, L., Cai, G., Chang, C., Miao, A. Y., Yu, X. L., Yang, Z. Z., et al. (2015). Diastolic Dysfunction Occurs Early in HER2-Positive Breast Cancer Patients Treated Concurrently with Radiation Therapy and Trastuzumab. *OncoLogist* 20 (6), 605–614. doi:10.1634/theoncologist.2014-0299

Capelan, M., Pugliano, L., De Azambuja, E., Bozovic, I., Saini, K. S., Sotiriou, C., et al. (2013). Pertuzumab: new hope for Patients with HER2-Positive Breast Cancer. *Ann. Oncol.* 24 (2), 273–282. doi:10.1093/annonc/mds328

Chaar, M., Kamta, J., and Ait-Oudhia, S. (2018). Mechanisms, Monitoring, and Management of Tyrosine Kinase Inhibitors-Associated Cardiovascular Toxicities. *Onco Targets Ther.* 11, 6227–6237. doi:10.2147/OTT.S170138

Chan, A., Delage, S., Holmes, F. A., Moy, B., Iwata, H., Harvey, V. J., et al. (2016). Neratinib after Trastuzumab-Based Adjuvant Therapy in Patients with HER2-Positive Breast Cancer (ExNE-T): a multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. *Lancet Oncol.* 17 (3), 367–377. doi:10.1016/S1470-2241(15)00551-3

Cochet, A., Quilichini, G., Dgyai-Cochet, I., Touzery, C., Toubeau, M., Berriolo-Riedinger, A., et al. (2011). Baseline Diastolic Dysfunction as a Predictive Factor of Trastuzumab-Mediated Cardiotoxicity after Adjuvant Anthracycline Therapy in Breast Cancer. *Breast Cancer Res. Treat.* 130 (3), 845–854. doi:10.1007/s10549-011-1714-9

Corti, C., and Crucisietti, C. (2021). Tucatinib Approval by EMA Expands Options for HER2-Positive Locally Advanced or Metastatic Breast Cancer. *ESMO open* 6 (2), 100063. doi:10.1016/j.esmoopen.2021.100063

Cote, G. M., Miller, T. A., Lebrasseur, N. K., Kuramochi, Y., and Sawyer, D. R. (2005). Neureilgulin-1alpha and Beta Isoform Expression in Cardiac Microvascular Endothelial Cells and Function in Cardiac Myocytes In Vitro. *Exp. Cell Res.* 311, 135–146. doi:10.1016/j.yexcr.2005.08.017

de Azambuja, E., Holmes, E., Di Cosimo, S., Sambé, R. F., Untch, M., Jackisch, C., et al. (2014). Lapatinib with Trastuzumab for HER2-Positive Early Breast Cancer (NeoALTO): Survival Outcomes of a Randomised, Open-Label, Multicentre, Phase 3 Trial and Their Association with Pathological Complete Response. *Lancet Oncol.* 15, 1137–1146. doi:10.1016/S1470-2241(14)03202-1

de Azambuja, E., Procter, N., Rastogi, P., Cecchini, R. S., Lambertini, M., Ballman, K., et al. (2020). A Pooled Analysis of the Cardiac Events in the Trastuzumab Adjuvant Trials. *Breast Cancer Res. Treat.* 179 (1), 161–171. doi:10.1007/s10549-019-05453-z

De Keulenaer, G. W., Doggen, K., and Lemmens, K. (2012). The Vulnerability of Heart as a Pluricellular Paracrine Organ: Lessons from Unexpected Triggers of Heart Failure in Targeted ErbB2 Anticancer Therapy. *Circ. Res.* 106, 35–40. doi:10.1161/CIRCRESAHA.109.205906

De Lorenzo, R., Riccio, G., Rea, D., Barbieri, A., Coppola, C., and Maurea, N. (2019). The Breast Cancer Treated in the Adjuvant Lapatinib And/or Trastuzumab Double-Blind Clinical Trial of Candesartan and Metoprolol. *Eur. Heart J.* 35 (15), 1671–1680. doi:10.1093/eurheartj/ehz022

De Konik, K., Procyk, D., Horyn, M. L., Niu, J., Zhang, N., Giordano, S. H., and Chavez-MacGregor, M. (2018). Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients. *JACC Cardiovasc. Imaging* 11, 1084–1093. doi:10.1016/j.jcmg.2018.06.005

Herrmann, J. (2020). Adverse Cardiac Effects of Cancer Therapies: Cardiotoxicity and Arrhythmia. *Nat. Rev. Cardiol.* 17 (8), 474–502. doi:10.1038/s41569-020-0348-1

Hojan, K., Proczyk, D., Horynyska-Kostewicz, D., Leporowska, E., and Litwinieniuk, M. (2019). The Preventive Role of Regular Physical Training in Ventricular Remodeling, Serum Cardiac Markers, and Exercise Performance Changes in Breast Cancer in Women Undergoing Trastuzumab Therapy-An REH-HER Study. *J. Clin. Med.* 9, 5. doi:10.3390/jcm9051379

Houbois, C. P., Nolan, M., Somerset, E., Shalmon, T., Esmaeilzadeh, M., Lamacie, M. M., et al. (2021). Serial Cardiovascular Magnetic Resonance Strain Measurements to Identify Cardiotoxicity in Breast Cancer: Comparison with Echocardiography. *JACC Cardiovasc. Imaging* 14 (5), 962–974. doi:10.1016/j.jcmg.2020.09.039

Hsu, W. T., Huang, C. Y., Yen, C. Y. T., Cheng, A. L., and Hsieh, P. C. H. (2018). The HER2 Inhibitor Lapatinib Potentiates Doxorubicin-Induced Cardiotoxicity through INOS Signaling. *Theranostics* 8, 3176–3188. doi:10.7150/thno.23207

Hussain, Y., Drill, E., Dang, C. T., Liu, J. E., Steingart, R. M., and Yu, A. F. (2019). Cardiac Outcomes of Trastuzumab Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Ejection Fraction. *Breast Cancer Res. Treat.* 175 (1), 239–246. doi:10.1007/s10549-019-05139-6

Jacquinot, Q., Paquet-Bailly, S., Fumoleau, P., Romieu, G., Pierga, J. Y., Espié, M., et al. (2018). Flucluation of the Left Ventricular Ejection Fraction in Patients with HER2-Positive Early Breast Cancer Treated by 12 Months of Adjuvant Trastuzumab. *Breast* 41, 1–7. doi:10.1016/j.breast.2018.06.001

Jerian, S., and Keegan, P. (1999). Cardiotoxicity Associated with Paclitaxel/trastuzumab Combination Therapy. *J. Clin. Oncol.* 17 (5), 1647–1648. doi:10.1200/jco.1999.17.5.1644e

Jerusalem, G., Lancelotti, P., and Kim, S. B. (2019). HER2+ Breast Cancer Treatment and Cardiotoxicity: Monitoring and Management. *Breast Cancer Res. Treat.* 177 (2), 237–250. doi:10.1007/s10549-019-05303-y
Khoury, K., Lynce, F., Barac, A., Geng, X., Dang, C., Yu, A. F., et al. (2021). Long-term Cardiotoxicity of ErbB2 Targeted Drugs. *Biomed. Pharmacother.* 93, 17–26. doi:10.1016/j.biopha.2017.06.033

Kaboré, E. G., Guencancia, C., Vaz-Luis, I., Di Meglio, A., Pistilli, B., Coutant, C., et al. (2019). Association of Body Mass index and Cardiotoxicity Related to Anthracyclines and Trastuzumab in Early Breast Cancer. *French CANTO Cohort Study. PloS Med.* 16, e1002989. doi:10.1371/journal.pmed.1002989

Kaplon, H., and Reichert, J. M. (2021). Antibodies to Watch in 2021. *Biomed. Pharmacother.* 1860476. doi:10.1016/S1470-2045(17)30717-9

Meyer, D., and Birchmeier, C. (1995). Multiple Essential Functions of Neuregulin in Development. *Nature* 378, 386–390. doi:10.1038/378386a0

Michel, L., Minuc, R. I., Mahabadi, A. A., Settelmeier, S., Al-Rashid, F., Rassaf, T., et al. (2020). Troponins and Brain Natriuretic Peptides for the Prediction of Cardiotoxicity in Cancer Patients: a Meta-Analysis. *Eur. J. Heart Fail.* 22 (2), 350–361. doi:10.1002/ejhf.1631

Midi, S., Saura, C., Yamashita, T., Park, Y. H., Kim, S. B., Tamura, K., et al. (2020). Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. *N. Engl. J. Med.* 382 (7), 610–621. doi:10.1056/NEJMoa1914510

Moy, B., Kirkpatrick, P., Kar, S., and Goss, P. (2007). Laptapitin. *Nat. Rev. Drug Discov.* 6, 431–432. doi:10.1038/nrd2332

Murthy, R. K., Loi, S., Okines, A., Papalopoulou, E., Hamilton, E., Hurvitz, S. A., et al. (2020). Tucatinib, Trastuzumab, and Cazectinab for HER2-Positive Metastatic Breast Cancer. *N. Engl. J. Med.* 382 (7), 597–609. doi:10.1056/NEJMa1914609

Narayan, P., Osgood, C. L., Singh, H., Chiu, H.-J., Ricks, T. K., Chiu Yuen Chow, E., et al. (2021). FDA Approval Summary: Fam-trastuzumab deruxtecan-Nkxi for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer, 22 Mar. 2021. *Clin. Cancer Res.* 27, 4478–4485. clincancerres. doi:10.1158/1078-0432.CCR-20-4557

Nicol, M., Sadoun, M., Polidano, E., Launay, J. M., Samuel, J. L., Azibani, F., et al. (2021). Doxorubicin-induced and Trastuzumab-Induced Cardiotoxicity in Mice Is Not Prevented by Metoprolol. *ESC Heart Fail.* 8 (2), 928–937. doi:10.1002/ehf2.13198

Nowsher, S., Aziz, K., Park, J. Y., Lerman, A., Villarraga, H. R., Ruddy, K. J., et al. (2018). Trastuzumab in Female Breast Cancer Patients with Reduced Left Ventricular Ejection Fraction. *J. Am. Heart Assoc.* 7 (15), e008637. doi:10.1161/ JAHA.118.008637

Oh, D. Y., and Bang, Y. J. (2020). HER2-targeted Therapies - a Role beyond Breast Cancer. *Nat. Rev. Clin. Oncol.* 17 (1), 33–48. doi:10.1038/s41571-019-0256-3

Oikonomou, E. K., Kokkinnis, D. G., Kampikis, P. N., Amir, E. A., Marwick, T. H., Gupta, D., et al. (2019). Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-Analysis. *JAMA Cardiol.* 4, 1007–1018. doi:10.1001/jamacardio.2019.2952

Oliva, S., Ciuffi, G., Frattini, S., Simoncini, E. L., Faggiano, P., Boccardi, L., et al. (2012). Administration of Angiotensin-Converting Enzyme Inhibitors and β-blockers during Adjuvant Trastuzumab Chemotherapy for Nonmetastatic Breast Cancer: Marker of Risk or Cardioprotection in the Real World?. *Oncolist* 17 (7), 917–924. doi:10.1634/theoncologist.2011-0445

Ohto, A., Engel, J. M., Stankowski, R. V., Liang, H., Berg, R. L., and Doi, S. A. (2012). High-sensitivity C-Reactive Protein (hs-CRP) as a Biomarker for Trastuzumab-Induced Cardiotoxicity in HER2-Positive Early-Stage Breast Cancer: A Pilot Study. *Breast Cancer Res. Treat.* 134, 291–298. doi:10.1007/s10549-012-2039-3

Ozcelik, C., Erdmann, B., Pilz, B., Wettchuck, N., Britsch, S., Hübner, N., et al. (2002). Conditional Mutation of the ErbB2 (HER2) Receptor in Cardiomyocytes Leads to Dilated Cardiomyopathy. *Proc. Natl. Acad. Sci. U S A.* 99, 8880–8885. doi:10.1073/pnas.122249299

Pavlo, N., Radder, M., Hülsmann, M., Nehou, S., Adlbrecht, C., Strunk, G., et al. (2015). Cardiovascular Biomarkers in Patients with Cancer and Their Association with All-Cause Mortality. *Heart* 101, 1874–1880. doi:10.1136/ heartjnl-2015-307848

Pentassuglia, L., Timolati, F., Seifriz, F., Abudakader, K., Suter, T. M., and Zuppinfer, C. (2007). Inhibition of ErbB2/neuregulin Signaling Augments

Yang et al. Cardiotoxicity of ErbB2 Targeted Drugs
Mechanism for Trastuzumab-Induced Cardiotoxicity. Circulation 105, 1551–1554. doi:10.1161/01.cir.0000133893.41224.1c
Seifian, S., Seiean, A., Plana, J. C., Budd, G. T., and Marwick, T. H. (2012). Effect of Statin Therapy on the Risk for Incident Heart Failure in Patients with Breast Cancer Receiving Anthracycline Chemotherapy: an Observational Clinical Cohort Study. J. Am. Coll. Cardiol. 60, 2384–2390. doi:10.1016/j.jacc.2012.07.067
Serrano, J. M., González, I., Del Castillo, S., Muñiz, J., Morales, L. J., Moreno, F., et al. (2015). Diastolic Dysfunction Following Anthracycline-Based Chemotherapy in Breast Cancer Patients: Incidence and Predictors. Oncologist 20 (8), 864–872. doi:10.1634/theoncologist.2014-0500
Shah, M., Wedam, S., Cheng, J., Fiero, M. H., Xia, H., Li, F., et al. (2021). FDA Approval Summary: Tucatinib for the Treatment of Patients with Advanced or Metastatic HER2-Positive Breast Cancer. Clin. Cancer Res. 27 (5), 1220–1226. doi:10.1158/1078-0432.CCR-20-2701
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. (1987). Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene. Science 235, 177–182. doi:10.1126/science.3798106
Tan, A. R., Im, S. A., Mattar, A., Colomer, R., Stroyakovskii, D., Nowecki, Z. L. (2021). Fixed-dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection Plus Chemotherapy in HER2-Positive Early Breast Cancer (Federa:ca): a Randomised, Open-Label, Multicentre, Non-inferiority, Phase 3 Study. Lancet Oncol. 22 (1), 85–97. doi:10.1016/S1470-2045(20)30536-2
Thavendiranathan, P., Negishi, T., Coté, M. A., Penicka, M., Massey, R., Cho, G. Y., et al. (2018). Single versus Standard Multiview Assessment of Global Longitudinal Strain for the Diagnosis of Cardiotoxicity during Cancer Therapy. JACC Cardiovasc Imaging 11, 1109–1118. doi:10.1016/j.jcmg.2018.03.003
Timolati, F., Ott, D., Pentassuglia, L., Giraud, M. N., Suter, T. M., Timolati, F., Ott, D., Pentassuglia, L., Giraud, M. N., Perriard, J. C., Suter, T. M., et al. (2013). Neurog1-1 Beta Attenuates Doxorubicin-Induced Alterations of Excitation-Contraction Coupling and Reduces Oxidative Stress in Adult Rat Cardiomyocytes. J. Mol. Cell. Cardiol 41 (5), 845–854. doi:10.1016/j.yjmcc.2006.08.002
Tkach, M., Rosenblit, C., Rivas, M. A., Proietti, C. J., Diaz Flaque, M. C., Mercogliano, M. F., et al. (2013). p42/p44 MAPK-Mediated Stat3erSR72 Phosphorylation Is Required for Progestin-Induced Full Activation of Stat3 and Breast Cancer Growth. Endocr. Relat. Cancer 20, 197–212. 22 Mar. 2013. doi:10.1530/ERC-12-0194
Upshaw, J. N. (2020). Cardioprotective Strategies to Prevent Cancer Treatment-Related Cardiovascular Toxicity: a Review. Curr. Oncol. Rep. 22 (7), 72. doi:10.1007/s11991-020-00992-w
Upshaw, J. N., Finkelman, B., Hubbard, R. A., Smith, A. M., Narayan, H. K., Arndt, L., et al. (2020). Comprehensive Assessment of Changes in Left Ventricular Diastolic Function with Contemporary Breast Cancer Therapy. JACC Cardiovasc Imaging 13 (1 Pt 2), 198–210. doi:10.1016/j.jcmg.2019.07.018
van Ramshorst, M. S., van Werkhoven, E., Honkko, A. H., Dezentjé, V. O., Oving, I. M., Mandjes, I. A., et al. (2016). Toxicity of Dual HER2-Blockade with Pertuzumab Added to Anthracycline versus Non-anthracyline Containing Chemotherapy as Neoadjuvant Treatment in HER2-Positive Breast Cancer: The Train-2 Study. Breast 29, 153–159. doi:10.1016/j.breast.2016.07.017
Berma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., et al. (2012). Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. N. Engl. J. Med. 367, 1783–1791. doi:10.1056/NEJMoa1209124
Visser, A., van den Vem, E. M., Ercuys, I. L., Blaise, R. J., van Halteren, H. K., Aken, K., et al. (2016). Cardiac Monitoring during Adjuvant Trastuzumab Therapy: Guideline Adherence in Clinical Practice. Acta Oncol 55 (4), 423–429. doi:10.3109/0282439X.2015.1086444
von Minckwitz, G., Huang, C. S., Mano, M. S., Loibl, S., Mamounas, E. P., Untch, M., et al. (2019). Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N. Engl. J. Med. 380 (7), 617–628. doi:10.1056/NEJMoa1814017
von Minckwitz, G., Procter, M., de Azambuja, E., Zardavas, D., Benyunes, M., Viale, G., et al. (2017). Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N. Engl. J. Med. 377 (2), 122–131. doi:10.1056/NEJMoa1703643

Walker, J. R., Sharma, A., Lytwyn, M., Bohonis, S., Thliveris, J., Singal, P. K., et al. (2011). The Cardioprotective Role of Probucol against Anthracycline and Trastuzumab-Mediated Cardiotoxicity. *J. Am. Soc. Echocardiogr* 24, 699–705. official publication of the American Society of Echocardiography. doi:10.1016/j.echo.2011.01.018

Yıldırım, A., Tunaoğlu, F. S., Kambur, K., and Pinarlı, F. G. (2013). The Utility of NT-proBNP and Various Echocardiographic Methods in the Determination of Doxorubicin Induced Subclinical Late Cardiotoxicity. *Kardiol Pol.* 71 (1), 40–46.

Yoon, H. J., Kim, K. H., Kim, H. Y., Park, H., Cho, J. Y., Hong, Y. J., et al. (2019). Impacts of Non-recovery of Trastuzumab-Induced Cardiomyopathy on Clinical Outcomes in Patients with Breast Cancer. *Clin. Res. Cardiol.* 108 (8), 892–900. doi:10.1007/s00392-019-01417-x

Zambetti, M., Montemurro, F., Morandi, P., Zamagni, C., Brandes, A. A., Bisagni, G., et al. (1990). Safety Profile of Subcutaneous Trastuzumab for the Treatment of Patients with HER2-Positive Early or Locally Advanced Breast Cancer: Primary Analysis of the SCHEARLY Study. *Eur. J. Cancer* 105 (2018), 61–70. Oxford, England. doi:10.1016/j.ejca.2018.09.034

Zhao, P., Zhang, Y., Li, W., Jeanty, C., Xiang, G., and Dong, Y. (2020). Recent Advances of Antibody Drug Conjugates for Clinical Applications. *Acta Pharm. Sin B* 10 (9), 1589–1600. doi:10.1016/j.apsb.2020.04.012

Zhao, Y. Y., Sawyer, D. R., Baliga, R. R., Opel, D. J., Han, X., Marchionni, M. A., et al. (1998). Neuregulins Promote Survival and Growth of Cardiac Myocytes. Persistence of ErbB2 and ErbB4 Expression in Neonatal and Adult Ventricular Myocytes. *J. Biol. Chem.* 273, 10261–10269. doi:10.1074/jbc.273.17.10261

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.